Adaptive Biotechnologies Corp Stock News

Adaptive Biotechnologies and Netflix were top contributors, driven by strong earnings, momentum in core businesses, and positive outlooks. UnitedHealth Group and Visa detracted from performance due to earnings weakness, guidance cuts, and potential disruption from stablecoins. We initiated a position in HubSpot for its strong SMB positioning, AI-driven growth, and scalable financials, while exi...

Just after market close, Adaptive Biotechnologies (ADPT 5.97%) took the wraps off its second quarter. The following day, investors reacted to this by bidding the biotech company's stock up by almost 6%.

Adaptive (ADPT) Q2 Revenue Surges 36%

Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Chad M. Robins - Co-Founder, CEO & Chairman Karina Calzadilla - Vice President of Investor Relations Kyle Piskel - VP, CFO & Principal Accounting Officer Susan Bobulsky - Chief Commercial Officer of MRD Conference Call Participants Andrew Frederick Brackmann - Will...

SEATTLE, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended June 30, 2025. “We delivered an outstanding second quart...

SEATTLE, July 15, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the second quarter 2025 after market close on Tuesday, August 5, 2025. Company manageme...

clonoSEQ® is now integrated into Flatiron Health's OncoEMR®, simplifying MRD testing access for over 4,500 clinicians across the Flatiron network.

SEATTLE, May 30, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that its next-generation sequencing (NGS)-based clonoSEQ® test for measurable residual disease (MRD) assessment will be inclu...